Jacobs Levy Equity Management’s Intellia Therapeutics NTLA Stock Holding History

Jacobs Levy Equity Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3M	Buy	726,057 +666,074	+1,110%	+$9.32M	0.04%	287
2026 Q1	$769K	Buy	+59,983	New	+$764K	﹤0.01%	756
2020 Q3	–	Sell	-16,764	Closed	-$352K	–	1083
2020 Q2	$352K	Sell	16,764 -60,674	-78%	-$1.03M	﹤0.01%	857
2020 Q1	$947K	Buy	77,438 +44,819	+137%	+$604K	0.01%	635
2019 Q4	$479K	Buy	+32,619	New	+$454K	﹤0.01%	788

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Jacobs Levy Equity Management's NTLA Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Intellia Therapeutics (NTLA) stake by 1,110% in Q2 2026, buying an estimated $9.32M and bringing the position to 726,057 shares worth $12.3M. The position accounts for 0.04% of the portfolio, ranked #287.

Jacobs Levy Equity Management first reported a position in NTLA in Q4 2019 and has held it in 5 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Jacobs Levy Equity Management held 726,057 shares of Intellia Therapeutics worth $12.3M as of Q2 2026.
Jacobs Levy Equity Management bought 666,074 Intellia Therapeutics shares in Q2 2026, an estimated $9.32M.
Intellia Therapeutics made up 0.04% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #287 holding.
Jacobs Levy Equity Management first reported a position in Intellia Therapeutics in Q4 2019 and has held it in 5 quarters since.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.